Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutrient label comments

This article was originally published in The Tan Sheet

Executive Summary

FDA extends to April 30 the deadline for comments on its proposed rulemaking concerning percent daily value information allowed on nutrition facts and supplement facts labels. The agency published an advanced notice of proposed rulemaking on Nov. 2 with a 90-day comment period. Dietary supplement industry stakeholders claim the proposal to use estimated average requirements to set daily values for the labels could reduce existing values and lead to lower nutrient levels in food (1"The Tan Sheet" Nov. 12, 2007, p. 3)...

You may also be interested in...



Industry Speaks Up Against Using EARs To Set Daily Nutrient Values

Dietary supplement industry stakeholders contend an FDA proposal to use estimated average requirements to set daily values for nutrition and supplement facts labels could reduce existing values and lead to lower nutrient levels in food

Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

Lack of detail on data elements that would be required through the portal has stakeholders wondering if the Centers for Medicare and Medicaid Services has really found a way to make the registry requirement less of a threat to access for Alzheimer’s drugs with traditional FDA approval.

Japan Nod For Quizartinib In First-Line AML

Japan’s decision gives quizartinib its first approval globally in specific first-line AML indication, in relatively small but high-need patient population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel